Key regions: Germany, South Korea, France, United States, United Kingdom
The demand for Anti-Coagulants in Ireland has been on the rise in recent years.
Customer preferences: Patients in Ireland have been increasingly preferring oral anticoagulants over traditional injectable ones. This trend is mainly due to the convenience of oral anticoagulants, which do not require frequent visits to the hospital for injections. Additionally, the preference for newer, more effective anticoagulants has been growing, which has led to increased demand for direct oral anticoagulants.
Trends in the market: The Anti-Coagulants market in Ireland is expected to grow at a steady pace in the coming years. The increasing prevalence of cardiovascular diseases and the growing geriatric population are the primary drivers of this growth. Additionally, the demand for anticoagulants is expected to increase due to the rising incidence of atrial fibrillation and deep vein thrombosis.
Local special circumstances: Ireland has a high prevalence of cardiovascular diseases, which has led to an increase in the demand for anticoagulants. Additionally, the country has a rapidly aging population, which is expected to further boost the demand for anticoagulants in the coming years. The Irish government has also been investing heavily in the healthcare sector, which has led to better access to healthcare services for the population.
Underlying macroeconomic factors: The Irish economy has been growing at a steady pace in recent years, which has led to an increase in the disposable income of the population. This has resulted in increased spending on healthcare services, including anticoagulants. Additionally, the Irish government has been investing heavily in the healthcare sector, which has led to better access to healthcare services for the population. The country's membership in the European Union has also played a significant role in the growth of the Anti-Coagulants market, as it has led to increased investment in the healthcare sector.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
